Cilostazol and Probucol for Cognitive Decline after Stroke: A Cognitive Outcome Substudy of the PICASSO Trial

Jae-Sung Lim,1 Sun U. Kwon,2 Kyung-Ho Yu,3 Sungwook Yu,4 Jong-Ho Park,4 Byung-Chul Lee,4 Mi Sun Oh,4 Yong-Jae Kim,5 Joung-Ho Rha,1 Yang-Ha Hwang,6 Ji Sung Lee,8 Sung Hyuk Heo,1 Seong Hwan Ahn,1 Woo-Keun Seo,7 Jong-Moo Park,1 Ju-Hun Lee,7 Jee-Hyun Kwon,7 Sung-II Sohn,7 Jin-Man Jung,9 Hahn Young Kim,1 Eung-Gyu Kim,1 Jae-Kwan Cha,1 Man-Seok Park,1 Hyo Suk Nam,10 Hee-Joon Bae,1 Dong-Eog Kim,11 Jaeseol Park,1 Yeonwook Kang,1 Jimi Choi,1 Juneyoung Lee,1

1Department of Neurology, Hallym University Sacred Heart Hospital, Hallym Neurological Institute, Hallym University College of Medicine, Anyang, Korea
2Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Neurology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
4Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea
5Department of Neurology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
6Department of Neurology, Inha University Hospital, Incheon, Korea
7Department of Neurology, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea
8Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea
9Department of Neurology, Kyung Hee University Medical Center, Seoul, Korea
10Department of Neurology, Chosun University Hospital, Gwangju, Korea
11Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
12Department of Neurology, Nowon Eulji Medical Center, Eulji University, Seoul, Korea
13Department of Neurology, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea
14Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
15Department of Neurology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea
16Department of Neurology, Korea University Ansan Hospital, Ansan, Korea
17Department of Neurology, Konkuk University School of Medicine, Seoul, Korea
18Department of Neurology, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea
19Department of Neurology, Dong-A University Hospital, Busan, Korea
20Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
21Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
22Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
23Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
24Department of Psychology, Hallym University, Chuncheon, Korea
25Department of Biostatistics, Korea University College of Medicine, Seoul, Korea
26BK21 FOUR R&E Center for Learning Health Systems, Korea University, Seoul, Korea

Dear Sir:

Previous clinical trials to prevent post-stroke cognitive impairment, such as Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) and Secondary Prevention of Small Subcortical Strokes (SPS3), failed to show clinically meaningful results.1,2 There is an evidence that cilostazol, a phosphodiesterase-3 inhibitor, could suppress cognitive decline in patients with dementia,3 and decrease amyloid beta accumulation.4 Probucol, a cholesteryl ester transfer protein activator with lipid-lowering and anti-oxidative effects, has a beneficial effect on cognition by inhibiting amyloid beta-induced hippocampal synaptic impairment.5 Thus, we aimed to determine the efficacy of cilostazol and probucol for preventing poststroke cogni-
tive decline in patients with multiple cerebral microbleeds (CMBs) or a history of prior intracerebral hemorrhage (ICH); a population that is expected to have a high risk for future cognitive decline.

Prevention of Cardiovascular events in Ischemic Stroke patients with high risk of cerebral hemorrhage for reducing Cognitive decline (PICASSO-COG) is a predetermined substudy of the PICASSO trial, which is a randomized double-blinded placebo-controlled trial with a 2x2 factorial design: cilostazol versus aspirin, and probucol versus no probucol. The design and analysis plan have been previously reported. The key inclusion criteria were non-cardioembolic ischemic stroke or transient ischemia attack and previous ICH or multiple CMBs on gradient echo imaging. Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) at randomization and at 4, 13, 25, 37, and 49 months after randomization. The cognitive function at the second visit (4 months after randomization) in patients who were randomized within 3 months after stroke was set as the baseline function, while the cognitive function at the first visit (1 month after enrollment) was set as the baseline for those randomized beyond 90 days after stroke. The baseline cognitive assessment was therefore conducted between 4 and 7 months after stroke onset in all participants eligible for the PICASSO-COG substudy. The primary outcome was a change in MMSE score, and a restricted maximum likelihood-based mixed effects model with repeated measurements was used. The efficacy of each treatment was analyzed separately because the interaction effect between the antiplatelets and lipid-lowering treatment was not significant. Detailed infor-

Changes from baseline to follow-up (MMSE)

Baseline 1st 2nd 3rd 4th
Cilostazol 451 449 301 181 66
Aspirin 441 439 292 180 72

Changes from baseline to follow-up (MoCA)

Baseline 1st 2nd 3rd 4th
Cilostazol 447 444 297 178 64
Aspirin 430 427 285 176 68

Changes from baseline to follow-up (MMSE)

Baseline 1st 2nd 3rd 4th
Probucol 459 456 303 197 82
No probucol 433 452 290 164 56

Changes from baseline to follow-up (MoCA)

Baseline 1st 2nd 3rd 4th
Probucol 452 447 298 192 77
No probucol 425 424 284 162 55

Figure 1. Mean changes in cognitive scores from baseline to each follow-up in (A, B) cilostazol vs. aspirin and (C, D) probucol vs. no probucol groups. (A, C) Mini-Mental State Examination (MMSE) and (B, D) Montreal Cognitive Assessment (MoCA).
tion on the analyses, including sensitivity and subgroup analyses, are presented in the Supplementary methods.

As shown in Supplementary Figure 1, among 1,382 subjects, 1,240 completed cognitive evaluations at randomization and 892 subjects (877 for the MoCA) were finally included (Supplementary Table 1). The baseline characteristics were not significantly different between the treatment groups, except the proportion of those with baseline MMSE ≤24 (Supplementary Table 2). Cilostazol did not show any significant differences in preventing cognitive decline in comparison with aspirin (Figure 1 and Supplementary Table 3). In the subgroup analysis according to the baseline MMSE score, the decrease in the MMSE score in the aspirin group of those with baseline MMSE ≤24 was more pronounced than that in the cilostazol group although the treatment effect was not significant (Supplementary Table 4). In the propensity score-matched subsets considering the baseline differences in the proportions of those with baseline MMSE ≤24, the cilostazol group showed a favorable outcome in those with mild to moderate white matter hyperintensities (WMHs) (Supplementary Table 5). Otherwise, no significant results were found in the subgroups and sensitivity analysis. Probucol treatment did not show any beneficial effect in the primary outcome using the MMSE. When analyzed according to the MoCA scores, probucol showed a favorable effect in preventing cognitive decline compared with the no probucol group (Supplementary Table 3). This effect was also observed in the subgroups without diabetes mellitus, with concomitant lipid-lowering agents, with baseline MMSE >24, and without severe WMH (Supplementary Table 4).

Longitudinal cognitive profiles of the study population might explain why this trial failed to prove the hypothesis. The demographics of the study subjects were comparable to those of the SPS3 trial. However, 69.3% of the PICASSO-COG subjects had moderate or severe WMH, while half of the subjects in the SPS3 had none or mild WMH. In this distinctive population, the magnitude of observed cognitive change was smaller than what we had expected. There are several reasons to consider. It has been reported that cognitive decline in patients with moderate to severe WMH was mainly observed in processing speed and executive function. In the SPS3 trial conducted in patients with lacunar infarction, verbal fluency was mainly impaired in addition to episodic memory. Memory dysfunction has also been reported to be affected by actually mediating executive dysfunction. Therefore, the MMSE was not sensitive enough to capture these long-term cognitive changes. The MoCA has been reported to be more sensitive to the stroke population than the MMSE; however, the MoCA total score seems inadequate to quantify changes over a 2-year study period. For subsequent clinical trials, neuropsychological tests that more sensitively assess changes over time in the target population, such as fluency, trail-making, and the Stroop test should be adopted. In another aspect, the active risk factor control in the trial setting might prevent the cognitive deterioration of study subjects, including the control group, and made it difficult to verify the effectiveness of the trial drug. This can be conceived from the findings from the previous trials for vascular cognitive impairment, which showed stable cognitive trajectories in placebo arms. Lastly, it is possible that the heterogeneity of WMH might have been affected. The theoretically hypothesized cognitive decline might not be actually observed in patients with WMH of causes other than ischemic origin. However, since the subjects of this trial had ischemic stroke based on the inclusion criteria and had preceding ICH/multiple CMBs, the proportion of these patients is not expected to be high.

We predetermined the time window of baseline cognitive evaluation between 4 and 7 months after entry event to minimize the effects of acute stroke on cognitive function. The intervals between index-stroke and baseline evaluations were 1 month in the ProFESS trial and 74 to 76 days in the SPS3 trial. If we were to include the spontaneous cognitive recovery after stroke in our analysis, the effects of the study medication could be exaggerated or underestimated.

As a limitation, the current study population did not seem to fulfill the criteria of reliable cognitive decline, and the trial needed much longer follow-up to show a significant change in the MMSE score. In addition, a treatment effect could have occurred between the index-stroke and the baseline assessment. Since we limited our analysis to those who underwent baseline evaluations for 4 to 7 months after index-stroke, we could not address this possibility in our analysis.

To the best of our knowledge, this is the first clinical trial comparing the efficacy of aspirin, cilostazol, and probucol in preventing poststroke cognitive decline. Cilostazol and probucol did not show any significant differences compared to aspirin and no probucol. However, when patients were assessed by the MoCA, probucol reduced cognitive decline after stroke.

Supplementary materials
Supplementary materials related to this article can be found online at https://doi.org/10.5853/jos.2020.03650.

References
1. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton

Lim et al. Cilostazol and Probucol for Post-Stroke Cognition
1. WA, et al. Effects of aspirin plus extended-release dipyramide versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. *Lancet Neurol* 2008;7:875-884.

2. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, et al. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. *Lancet Neurol* 2014;13:1177-1185.

3. Ihara M, Nishino M, Taguchi A, Yamamoto Y, Hattori Y, Saito S, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. *PLoS One* 2014;9:e89516.

4. Park SH, Kim JH, Bae SS, Hong KW, Lee DS, Leem JY, et al. Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation. *Biochem Biophys Res Commun* 2011;408:602-608.

5. Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice. *Exp Neurol* 2012;233:767-775.

6. Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, et al. Prevention of cardiovascular events in Asian patients with ischemic stroke at high risk of cerebral haemorrhage (PI-CASSO): a multicentre, randomised controlled trial. *Lancet Neurol* 2018;17:509-518.

7. Yu KH, Hong KS, Oh MS, Lee J, Lee JS, Kwon SU, et al. Design and rationale for a cognitive outcome sub-study in ischemic stroke patients with high risk of cerebral hemorrhage. *J Stroke Cerebrovasc Dis* 2016;25:2061-2066.

8. Jokinen H, Kalska H, Mäntylä R, Ylioski R, Hietanen M, Pohjasaava T, et al. White matter hyperintensities as a predictor of neuropsychological deficits post-stroke. *J Neurol Neurosurg Psychiatry* 2005;76:1229-1233.

9. Jacova C, Pearce LA, Costello R, McClure LA, Holliday SL, Hart RG, et al. Cognitive impairment in lacunar strokes: the SPS3 trial. *Ann Neurol* 2012;72:351-362.

10. Black S, Román GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. *Stroke* 2003;34:2323-2330.

11. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol* 2010;9:689-701.

12. Sachdev PS, Lo JW, Crawford JD, Mellon L, Hickey A, Williams D, et al. STROKOG (stroke and cognition consortium): an international consortium to examine the epidemiology, diagnosis, and treatment of neurocognitive disorders in relation to cerebrovascular disease. *Alzheimers Dement (Amst)* 2016;7:11-23.

Correspondence: Kyung-Ho Yu
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym Neurological Institute, Hallym University College of Medicine, 22 Gwanpyeong-ro 170beon-gil, Dongan-gu, Anyang 14068, Korea
Tel: +82-31-380-3740
Fax: +82-31-381-9474
E-mail: ykh1030@hallym.ac.kr
https://orcid.org/0000-0002-8997-5626

Co-correspondence: Sun U. Kwon
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-3960
Fax: +82-2474-4691
E-mail: sukwon@amc.seoul.kr
https://orcid.org/0000-0001-8302-331X

Received: August 31, 2020
Revised: November 14, 2020
Accepted: November 18, 2020

This work was supported by Korea Otsuka Pharmaceutical Company. Sun U. Kwon declares grants from Korea Otsuka Pharmaceutical Company. All other authors declare no competing interests.
Supplementary methods

The Prevention of Cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage for reducing COGNitive decline (PICASSO-COG) substudy was conducted only in South Korea (59 centers) because the cognitive assessment tools had not been validated by cross-cultural studies in each language.

The primary outcome was the change in Mini-Mental State Examination (MMSE) score over time from baseline in an intention-to-treat population. A restricted maximum likelihood-based mixed effects model with repeated measurements (MMRM) was used to compare cognitive changes over time between groups. The model included the fixed categorical effects of treatment group and sex as well as fixed continuous covariates of the patient’s age, duration of education, number of visits, baseline cognitive scores, and the National Institutes of Health Stroke Scale (NIHSS) score. The effect of the study sites was adjusted as a random factor in the model. An unstructured covariance structure, common to the treatments, was used to model the within-subject correlation.

Although this study had a 2×2 factorial design, the efficacy of each treatment was analyzed separately because the interaction effect between the antiplatelets and lipid-lowering treatment was not significant.

As cognitive impairment is an independent risk factor for attrition in a longitudinal study, we performed sensitivity analysis to examine its influence on cognitive outcome. Sensitivity analyses included the following: (1) a restricted maximum likelihood-based MMRM analysis with further adjustment for the participant’s drop-out status during the trial period as well as treatment status at the previous visit, which is defined as the patient missing the cognitive evaluation in the scheduled visit before the current visit, in the model; (2) MMRM analyses of participants’ cognitive evaluation at baseline and follow-up visits at 13, 25, 37, and 49 months; (3) MMRM analyses of participants who completed all scheduled visits during the following periods: baseline to 13 months, baseline to 25 months, baseline to 37 months, and baseline to 49 months; and (4) MMRM analyses of participants with ischemic stroke as an entry event excluding transient ischemic attack.

The primary outcome between the comparative arms was compared for the following subgroups: diabetes versus non-diabetes, mild to moderate (Fazekas grade 0–2) versus severe (Fazekas grade 3) white matter hyperintensities on magnetic resonance imaging, baseline MMSE ≤24 versus >24, and concomitant use of statin versus non-use. The same analyses as performed in the sensitivity and subgroup analyses were re-conducted in the propensity score matched subsets, which were constructed using the variables of subject age, sex, educational years, baseline cognitive score, and baseline NIHSS score to overcome the differences between the treatment groups arising from non-random missing in this substudy.

The longitudinal change in MoCA was also evaluated using the same statistical methods. A two-sided P-value of 0.05 was used to indicate statistical significance. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
**Supplementary Table 1. Baseline characteristics of the included and excluded subjects**

| Characteristic | PICASSO-COG study | MMSE analysis | MoCA analysis |
|---------------|-------------------|---------------|---------------|
|               | Included (n=1,240) | Excluded (n=142) | p | Included (n=892) | Excluded (n=348) | p | Included (n=877) | Excluded (n=363) | p |
| Age (yr)      | 65.8±10.8         | 68.3±10.0     | 0.01 | 64.9±10.8 | 68.2±10.5 | <0.01 | 64.8±10.8 | 68.3±10.4 | <0.01 |
| Female sex    | 480 (38.7)        | 53 (37.3)     | 0.75 | 327 (36.7) | 153 (44.0) | 0.02 | 318 (36.3) | 162 (44.6) | 0.01 |
| Education (yr)| 9 (6–12)          | 9 (6–12)      | 0.41 | 9 (6–12) | 6 (5–12)  | <0.01 | 9 (6–12) | 6 (5–12)  | <0.01 |
| Hypertension  | 1,091 (80.0)      | 133 (93.7)    | 0.04 | 796 (89.2) | 295 (84.8) | 0.03 | 783 (89.3) | 308 (84.9) | 0.03 |
| Diabetes      | 389 (31.4)        | 53 (37.3)     | 0.15 | 276 (30.9) | 113 (32.5) | 0.60 | 271 (30.9) | 118 (32.5) | 0.58 |
| Hyperlipidemia| 511 (41.2)        | 54 (38.0)     | 0.47 | 373 (41.8) | 138 (40.0) | 0.49 | 369 (42.1) | 142 (39.1) | 0.34 |
| Use of lipid-lowering agent* | 969 (78.2) | 85 (59.9) | <0.01 | 695 (77.9) | 274 (78.7) | 0.75 | 686 (78.2) | 283 (78.0) | 0.92 |
| Coronary artery disease | 59 (4.8) | 8 (5.6) | 0.65 | 37 (4.2) | 22 (6.3)  | 0.11 | 37 (4.2) | 22 (6.1)  | 0.17 |
| Smoking       | 546 (44.0)        | 65 (45.8)     | 0.69 | 407 (45.6) | 139 (39.9) | 0.07 | 404 (46.1) | 142 (39.1) | 0.02 |
| Index event   | 0.01              | 0.18          | 0.05 | 135.4     | 80.1      | 0.08 | 135.1     | 80.2      | 0.08 |
| Ischemic stroke | 1,175 (94.8) | 142 (100.0)  | <0.01 | 850 (95.3) | 325 (93.4) | 0.38 | 838 (95.6) | 337 (92.8) | 0.05 |
| Transient ischemic attack | 65 (5.2) | 0 (0.0) | 0.01 | 42 (4.7) | 23 (6.6)  | 0.39 | 39 (4.5) | 26 (7.2)  | 0.26 |
| Baseline NIHSS| 1 (0–3)           | 3 (1–5)       | <0.01 | 1 (0–3) | 2 (1–4)   | <0.01 | 1 (0–3) | 2 (1–4)   | <0.01 |
| Baseline MMSE | 26 (21–28)        | -             | -     | 26 (23–29) | 24 (17–27) | <0.01 | 26 (23–29) | 24 (17–27) | <0.01 |
| 24 or less    | 492 (39.7)        | -             | -     | 313 (35.1) | 179 (51.4) | <0.01 | 303 (34.6) | 189 (52.1) | <0.01 |
| >24           | 748 (60.3)        | -             | -     | 579 (64.9) | 169 (48.6) | 0.07 | 574 (65.4) | 174 (47.9) | 0.09 |
| Baseline MoCA | 20 (14–24)        | -             | -     | 20 (16–24) | 17 (10–22) | <0.01 | 20 (16–24) | 17 (10–22) | <0.01 |
| Treatment     |                   |               |       |           |           |       |           |           |       |
| Cilostazol    | 618 (49.8)        | 71 (50.0)     | 0.97 | 451 (50.6) | 167 (48.0) | 0.42 | 447 (51.0) | 171 (47.1) | 0.22 |
| Probucol      | 622 (50.2)        | 69 (48.6)     | 0.72 | 459 (51.5) | 163 (46.8) | 0.14 | 452 (51.5) | 170 (46.8) | 0.13 |
| SBP (mm Hg)   | 135.4±18.4        | 133.7±19.1    | 0.30 | 135.4±18.6 | 135.5±17.8 | 0.96 | 135.3±18.7 | 135.6±17.6 | 0.79 |
| DBP (mm Hg)   | 80.1±11.8         | 80.9±12.2     | 0.03 | 80.1±11.8 | 80.2±11.8 | 0.88 | 80.1±11.9 | 80.2±11.6 | 0.85 |
| BP readings   | 7 (4–13)          | 10 (3–18)     | 0.01 | 9 (6–13) | 2 (1–4)   | <0.01 | 9 (6–13) | 2 (1–4)   | <0.01 |
| Follow-up periods (yr) | 1.9 (1.0–3.0) | 2.7 (0.6–4.5) | <0.01 | 2.1 (1.3–3.0) | 0.5 (0.1–1.1) | <0.01 | 2.1 (1.3–3.0) | 0.6 (0.1–1.1) | <0.01 |
| Severe WMH    | 324 (27.1)        | 30 (22.1)     | 0.21 | 210 (24.5) | 114 (33.5) | <0.01 | 206 (24.4) | 118 (33.2) | <0.01 |
| Outcome events|                   |               |       |           |           |       |           |           |       |
| Recurrent stroke* | 102 (8.2) | 9 (6.3) | 0.43 | 44 (4.9) | 58 (16.7) | <0.01 | 41 (4.7) | 61 (16.8) | <0.01 |
| Ischemic      | 80 (6.5)          | 8 (5.6)       | 0.71 | 31 (3.5) | 49 (14.1)  | <0.01 | 30 (3.4) | 50 (13.8) | <0.01 |
| Hemorrhagic   | 23 (1.9)          | 1 (0.7)       | 0.50 | 14 (1.6) | 9 (2.6)    | 0.23 | 12 (1.4) | 11 (3.0)  | 0.048 |
| Myocardial infarction | 8 (0.7) | 1 (0.7) | 0.99 | 3 (0.3) | 5 (1.4)    | 0.04 | 3 (0.3) | 5 (1.4)  | 0.04 |
| Death         | 39 (3.2)          | 9 (6.3)       | 0.08 | 17 (1.9) | 22 (6.3)   | <0.01 | 17 (1.9) | 22 (6.1)  | <0.01 |

Values are presented as mean±standard deviation, number (%), or median [interquartile range]. Severe white matter hyperintensities were defined as Fazekas grade 3.

PICASSO-COG, Prevention of Cardiovascular events in Ischemic Stroke patients with high risk of cerebral hemorrhage for reducing COgnitive decline; MMSE, Mini–Mental State Examination; MoCA, Montreal Cognitive Assessment; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; DBP, diastolic blood pressure; BP, blood pressure; WMH, white matter hyperintensity.

*Prior to randomization; †One subject had both ischemic and hemorrhagic stroke and was counted as a duplicate.
**Supplementary Table 2.** Baseline characteristics of the study subjects

| Characteristic | Antiplatelet treatment | Lipid-lowering treatment |
|----------------|------------------------|--------------------------|
|                | Cilostazol (n=451)     | Aspirin (n=441)          | Probucol (n=459)    | No probucol (n=433) |
| Age (yr)       | 65.0±10.8              | 64.8±10.8                | 64.7±10.8           | 65.2±10.8           |
| Male sex       | 283 (62.7)             | 282 (63.9)               | 290 (63.2)          | 275 (63.5)          |
| Education (yr) | 9 (6–12)               | 9 (6–12)                 | 9 (6–12)            | 9 (6–12)            |
| Entry event    |                        |                          |                        |                      |
|                | Ischemic stroke        | 432 (95.8)               | 418 (94.8)           | 441 (96.1)          | 409 (94.5)          |
|                | Transient ischemic attack | 19 (4.2)            | 23 (5.2)             | 18 (3.9)            | 24 (5.5)            |
| Index of high risk of ICH |                |                          |                        |                      |
|                | Prior history of ICH   | 69 (15.3)                | 76 (17.2)            | 72 (15.7)           | 73 (16.9)           |
|                | Imaging findings of ICH without clinical history | 83 (18.4) | 77 (17.5) | 87 (18.9) | 73 (16.9) |
| Multiple microbleeds ≥2 |                | 299 (66.3)               | 288 (65.3)           | 300 (65.4)          | 287 (66.3)          |
| Time-to-randomization since entry event (day) | | | | | |
| ≤10            | 130 (28.8)             | 132 (29.9)               | 128 (27.9)           | 134 (30.9)          |
| 11–30          | 177 (39.2)             | 173 (39.2)               | 180 (39.2)           | 170 (39.3)          |
| 31–90          | 93 (20.6)              | 93 (21.1)                | 95 (20.7)            | 91 (21.0)           |
| >90            | 51 (11.3)              | 43 (9.8)                 | 56 (12.2)            | 38 (8.8)            |
| Baseline NIHSS | 1 (0–3)                | 1 (0–3)                  | 1 (0–3)              | 1 (0–3)             |
| Baseline MMSE | 26 (22–28)             | 27 (23–29)               | 26 (22–28)           | 26 (23–29)          |
| Baseline MoCA | 173 (38.4)             | 140 (31.7)               | 160 (34.9)           | 153 (35.3)          |
| Time-to-baseline MMSE since entry event (day) | | | | |
| ≤10            | 136 (125–148)          | 135 (127–151)            | 136 (126–151)        | 135 (127–148.5)     |
| Risk factors   |                        |                          |                        |                      |
| Hypertension   | 402 (89.1)             | 394 (89.3)               | 411 (89.5)           | 385 (88.9)          |
| Diabetes mellitus | 134 (29.7)        | 142 (32.2)               | 136 (29.6)           | 140 (32.3)          |
| Dyslipidemia   | 183 (40.6)             | 190 (43.1)               | 206 (44.9)           | 167 (38.6)          |
| Current smoking| 93 (20.6)              | 102 (23.1)               | 103 (22.4)           | 92 (21.2)           |
| Coronary artery disease | 15 (3.3)           | 22 (5.0)                 | 22 (4.8)             | 15 (3.5)            |
| Lipids (mg/dL) |                        |                          |                        |                      |
| Total cholesterol | 165.7±39.2          | 169.0±41.1               | 170.5±40.8           | 164.0±39.3          |
| LDL-C          | 101.0±36.0             | 102.7±35.4               | 104.7±36.4           | 98.7±34.7           |
| HDL-C          | 45.2±11.7              | 45.9±12.1                | 45.5±12.1            | 45.5±11.7           |
| Fazekas score for WMH |                  |                          |                        |                      |
| 0              | 0 (0.0)                | 0 (0.0)                  | 0 (0.0)              | 0 (0.0)             |
| 1              | 122 (27.1)             | 141 (32.0)               | 130 (29.1)           | 133 (32.4)          |
| 2              | 194 (43.0)             | 191 (43.3)               | 213 (47.6)           | 172 (41.8)          |
| 3              | 112 (24.8)             | 98 (22.2)                | 104 (23.3)           | 106 (25.8)          |
| Concomitant therapy |                  |                          |                        |                      |
| Aspirin (after randomization) | 218 (47.5)      | 223 (51.5)               | 241 (52.5)           | 210 (48.5)          |
| Cilostazol (after randomization) | 241 (53.4)       | 218 (49.4)               | 241 (52.5)           | 210 (48.5)          |
| Probucol       | 355 (79.1)             | 353 (80.2)               | 360 (78.8)           | 348 (80.6)          |
| Other lipid-lowering agents |                  |                          |                        |                      |

Values are presented as mean±standard deviation, number (%), or median (interquartile range). ICH, intracerebral hemorrhage; NIHSS, National Institutes of Health Stroke Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; WMH, white matter hyperintensity.
### Supplementary Table 3. MMRM analysis in cilostazol vs. aspirin and probucol vs. no probucol groups

| Time point      | Cilostazol vs. aspirin | Probucol vs. no probucol |
|-----------------|------------------------|--------------------------|
|                 | MMSE                   | MoCA                     | MMSE                   | MoCA                     |
| Cilostazol (n=451) | Aspirin (n=441) | p | Cilostazol (n=447) | Aspirin (n=430) | p | Probucol (n=458) | No probucol (n=433) | p | Probucol (n=452) | No probucol (n=425) | p |
| Baseline        | 24.76±4.48             | 25.07±4.89               | 0.81*                   | 18.98±6.16             | 19.67±6.31               | 0.31*                   | 24.93±4.73             | 24.90±4.65             | 0.57*                   | 19.23±6.15             | 19.42±6.33               | 0.01*                   |
| 1st Follow-up   | 24.85±4.65             | 25.10±4.95               | <0.01*                  | 19.02±6.37             | 19.78±6.62               | 0.045†                  | 25.00±5.03             | 24.94±4.55             | <0.01†                  | 19.44±6.43             | 19.34±6.58               | 0.03†                   |
| 2nd Follow-up   | 24.61±5.12             | 25.13±4.92               | 18.75±6.66              | 19.91±6.57             | 24.91±5.03               | 24.83±5.03              | 19.31±6.81             | 19.33±6.46              |
| 3rd Follow-up   | 24.56±5.29             | 24.82±5.35               | 19.01±6.80              | 19.43±6.96             | 24.81±5.17               | 24.54±5.48              | 19.67±6.72             | 18.69±7.04              |
| 4th Follow-up   | 23.97±5.51             | 25.15±5.41               | 18.69±7.34              | 20.62±6.98             | 24.41±5.69               | 24.84±5.17              | 19.91±7.48             | 19.36±6.82              |

Values are presented as mean±standard deviation. *P*-values for treatment-by-time interaction were not significant in any analysis.

MMRM, maximum likelihood-based mixed effects model with repeated measurements; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment.

*P*-value for MMRM for treatment effect; †P*-value for MMRM for the time effect.
### Supplementary Table 4. Subgroup analysis of the cilostazol/aspirin groups and probucol/no probucol groups

| Variable | Baseline | 1st Follow-up | 2nd Follow-up | 3rd Follow-up | 4th Follow-up |
|----------|----------|---------------|---------------|---------------|---------------|
| **Cilostazol/aspirin MMSE scores**<br>Baseline MMSE $\leq 24$ (n=313) | | | | | |
| Cilostazol (n=173) | 20.10±3.56 | 20.70±4.52 | 19.84±5.03 | 19.94±5.26 | 19.40±5.21 |
| Aspirin (n=140) | 19.23±4.41 | 19.73±5.10 | 20.01±5.44 | 19.67±5.90 | 16.54±6.15 |
| $P$ | 0.83* | 0.01* | | | |
| Baseline MMSE $>24$ (n=579) | | | | | |
| Cilostazol (n=278) | 27.66±1.65 | 27.41±2.30 | 27.28±2.62 | 27.40±2.64 | 26.76±3.46 |
| Aspirin (n=301) | 27.79±1.65 | 27.56±2.14 | 27.34±2.39 | 27.26±2.67 | 27.26±2.16 |
| $P$ | 0.82* | 0.01* | | | |
| **Probucol/no probucol MoCA scores**<br>Diabetes mellitus (n=271) | | | | | |
| Probucol (n=135) | 18.70±6.29 | 18.68±6.61 | 18.17±6.80 | 18.16±6.85 | 18.59±8.46 |
| No probucol (n=136) | 18.82±6.06 | 18.71±6.14 | 18.52±6.00 | 17.72±6.28 | 18.05±6.76 |
| $P$ | 0.16* | 0.18 | | | |
| No diabetes mellitus (n=606) | | | | | |
| Probucol (n=317) | 19.45±6.09 | 19.77±6.34 | 19.77±6.78 | 20.19±6.61 | 20.28±7.22 |
| No probucol (n=289) | 19.70±6.45 | 19.63±6.77 | 19.72±6.65 | 19.21±7.40 | 20.24±6.82 |
| $P$ | 0.02* | 0.38* | | | |
| Concomitant lipid-lowering agents (n=699) | | | | | |
| Probucol (n=355) | 19.46±6.08 | 19.73±6.28 | 19.81±6.60 | 20.06±6.51 | 20.69±7.19 |
| No probucol (n=344) | 19.47±6.35 | 19.44±6.62 | 19.59±6.38 | 19.23±6.70 | 19.45±6.73 |
| $P$ | 0.08* | 0.38* | | | |
| No concomitant lipid-lowering agents (n=175) | | | | | |
| Probucol (n=95) | 18.35±6.41 | 18.44±6.94 | 17.71±7.30 | 18.58±7.28 | 17.06±8.23 |
| No probucol (n=80) | 19.21±6.34 | 18.84±6.46 | 18.30±6.75 | 16.62±7.95 | 19.13±7.30 |
| $P$ | 0.03* | 0.03* | | | |
| Baseline MMSE $\leq 24$ (n=303) | | | | | |
| Probucol (n=155) | 12.94±4.90 | 12.90±5.11 | 12.60±5.79 | 13.21±5.82 | 11.92±6.41 |
| No probucol (n=148) | 12.86±5.10 | 12.78±5.13 | 12.17±4.89 | 11.61±5.64 | 8.55±5.43 |
| $P$ | 0.18* | <0.01* | | | |
| Baseline MMSE $>24$ (n=574) | | | | | |
| Probucol (n=297) | 22.51±3.69 | 22.78±4.03 | 22.75±4.26 | 23.14±4.10 | 23.75±4.22 |
| No probucol (n=277) | 22.92±3.52 | 22.82±4.17 | 22.55±4.05 | 22.42±4.30 | 22.07±3.77 |
| $P$ | 0.1* | 0.88* | | | |
| Mild to moderate white matter hyperintensities (n=637) | | | | | |
| Probucol (n=338) | 20.37±5.51 | 20.75±5.86 | 20.70±6.10 | 20.97±5.95 | 21.42±6.42 |
| No probucol (n=299) | 20.48±5.91 | 20.43±6.15 | 20.47±5.76 | 20.16±6.10 | 20.85±5.28 |
| $P$ | <0.01* | 0.40* | | | |
| Severe white matter hyperintensities (n=206) | | | | | |
| Probucol (n=102) | 15.49±6.58 | 15.18±6.44 | 14.69±7.06 | 15.35±7.41 | 14.20±8.85 |
| No probucol (n=104) | 16.35±6.61 | 16.03±6.82 | 15.99±7.24 | 14.05±7.87 | 15.30±9.29 |
| $P$ | 0.79* | 0.01* | | | |

Values are presented as mean±standard deviation. Mild to moderate white matter hyperintensities were defined as Fazekas grade 1 or 2, and severe white matter hyperintensities as Fazekas grade 3. $P$-values for treatment by time interactions were not significant for any analysis. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment. *$P$-value by MMRM for the treatment effect; †$P$-value by MMRM for the time effect.
**Supplementary Table 5.** Comparisons of MMSE scores between cilostazol and aspirin group according to severity of white matter changes in propensity score matched subsets

| MMSE scores    | Mild to moderate white matter hyperintensities (n=574) | Severe white matter hyperintensities (n=148) |
|----------------|--------------------------------------------------------|---------------------------------------------|
|                | Cilostazol (n=287) | Aspirin (n=287) | P                          | Cilostazol (n=74) | Aspirin (n=74) | P                          |
| Baseline       | 25.85±3.79         | 25.85±4.25      | 0.02*                      | 22.66±4.69        | 22.27±6.01      | 0.12*                      |
| 1st Follow-up  | 26.14±3.59         | 25.99±4.36      | 0.26†                      | 21.95±5.36        | 22.01±5.72      | <0.01†                     |
| 2nd Follow-up  | 26.08±3.99         | 25.83±4.05      | 0.26†                      | 21.79±5.85        | 21.74±6.81      |                            |
| 3rd Follow-up  | 26.43±3.30         | 25.47±4.63      |                            | 20.03±6.53        | 21.47±7.16      |                            |
| 4th Follow-up  | 26.30±3.06         | 25.75±5.18      |                            | 16.90±6.87        | 20.73±7.04      |                            |

Values are presented as mean±standard deviation. The propensity score was calculated using variables, including the participant’s age, sex, duration of education, baseline National Institutes of Health Stroke Scale (NIHSS) score, baseline MMSE score, baseline Montreal Cognitive Assessment (MoCA) score, coronary artery disease (yes/no), hypertension (yes/no), systolic blood pressure, and pattern of measurement within each white matter hyperintensity. Mild to moderate white matter hyperintensities were defined as Fazekas grade 1 or 2, and severe white matter hyperintensities as Fazekas grade 3. P-values for treatment by time interactions were not significant for any analysis.

MMSE, Mini-Mental State Examination.

*P*-value by MMRM for the treatment effect; †*P*-value by MMRM for the time effect.
Supplementary Figure 1. Flow diagram of subject enrollment. PICASSO-COG, Prevention of Cardiovascular events in Ischemic Stroke patients with high risk of cerebral hemorrhage for reducing COgnitive decline; MMSE, Mini-Mental State Examination.